Evidence map›Paper›PMID 34228224›Full record

ArticleJournal of cancer research and clinical oncology2022

Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma.

Chieh-Lung Cheng, Wei-Quan Fang, Yu-Jen Lin, Chang-Tsu Yuan, Bor-Sheng Ko, Jih-Luh Tang, Hwei-Fang Tien

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Chieh-Lung ChengGraduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan. jerome010471@gmail.com.ORCID http://orcid.org/0000-0001-5442-1079
Wei-Quan FangInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Yu-Jen LinDepartment of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Chang-Tsu YuanDepartment of Pathology, National Taiwan University Cancer Center, Taipei, Taiwan.
Bor-Sheng KoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan.
Jih-Luh TangDepartment of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Hwei-Fang TienDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan.
National Taiwan University · TWNational Taiwan University Hospital · TWInstitute of Biomedical Sciences, Academia Sinica · TW

Funding

Ministry of Science and Technology, Taiwan 108-2314-B-002-074Ministry of Science and Technology, Taiwan 109-2314-B-002-276
6 · The paper itself

Abstract

purposeStudies have reported a positive association between hepatitis B surface antigen (HBsAg)-positive hepatitis B virus (HBV) infection and follicular lymphoma (FL). Nevertheless, clinical information concerning chronic HBV infection in FL is sparse.

methodsThis retrospective cohort study investigated the prognostic impact of HBsAg in immunocompetent patients with FL treated with frontline rituximab-containing chemoimmunotherapy in an HBV-endemic area between 2006 and 2016.

resultsAmong the 149 analyzed patients, 32 (21.5%) were HBsAg-positive. HBsAg positivity was positively associated with symptomatic splenomegaly, significant serous effusions, and peritreatment hepatic dysfunction. HBsAg-positive patients had a trend of lower complete remission rate (59.4% vs. 76.9%, P = 0.07), significantly poorer overall survival (hazard ratio for death, 2.68; 95% confidence interval, 1.21-5.92), and shorter progression-free survival than had HBsAg-negative patients. Multivariate analysis revealed that HBsAg is an independent adverse prognostic factor for overall survival. Intriguingly, HBsAg-positive patients had a higher incidence of progression of disease within 24 months (POD24) than had HBsAg-negative patients (cumulative incidence rate, 25.8% vs. 12.4%, P = 0.045).

conclusionThis study revealed that patients with FL and chronic HBV infection represent a distinct subgroup with a markedly poor prognosis. HBsAg was positively associated with POD24 and might serve as a new prognostic predictor of the survival of FL patients in endemic regions for HBV infection.

Indexed as

Hepatitis BLymphoma, FollicularHepatitis B Surface AntigensHepatitis B virusHumansPrognosisRetrospective StudiesRituximabHepatitis B Surface AntigensRituximabFollicular lymphomaHBsAgHBV infectionPOD24Prognosis

Identifiers

PMID34228224
PMCPMC11800846
OpenAlexW3179654364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.